A carregar...
The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer
The anti-ErbB2 antibody trastuzumab has shown significant clinical benefits in ErbB2-overexpressing breast and gastric cancer, but resistance to the drug is common. Here, we investigated the antitumor activity of the combination of trastuzumab and the SRC inhibitor saracatinib in ErbB2-overexpressin...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Landes Bioscience
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3984329/ https://ncbi.nlm.nih.gov/pubmed/24492292 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.27443 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|